Keywords: $BRAF^{V600E}$ mutation; $BRAF^{non-V600E}$ mutation; RAS mutation; metastatic colorectal cancer; anti-epidermal growth factor receptor monoclonal antibody

Clinical significance of *BRAF* non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Eiji Shinozaki^{1,19}, Takayuki Yoshino^{*2,19}, Kentaro Yamazaki³, Kei Muro⁴, Kensei Yamaguchi^{5,20}, Tomohiro Nishina⁶, Satoshi Yuki⁷, Kohei Shitara², Hideaki Bando², Sachiyo Mimaki⁸, Chikako Nakai^{8,9}, Koutatsu Matsushima^{8,9}, Yutaka Suzuki¹⁰, Kiwamu Akagi¹¹, Takeharu Yamanaka^{12,21}, Shogo Nomura¹³, Satoshi Fujii¹⁴, Hiroyasu Esumi¹⁵, Masaya Sugiyama¹⁶, Nao Nishida¹⁶, Masashi Mizokami¹⁶, Yasuhiro Koh¹⁷, Yukiko Abe⁹, Atsushi Ohtsu¹⁸ and Katsuya Tsuchihara⁸

Background: Patients with $BRAF^{V600E}$ -mutated metastatic colorectal cancer (mCRC) have a poorer prognosis as well as resistance to anti-EGFR antibodies. However, it is unclear whether *BRAF* mutations other than $BRAF^{V600E}$ ($BRAF^{non-V600E}$ mutations) contribute to anti-EGFR antibody resistance.

Methods: This study was composed of exploratory and inference cohorts. Candidate biomarkers identified by whole exome sequencing from super-responders and nonresponders in the exploratory cohort were validated by targeted resequencing for patients who received anti-EGFR antibody in the inference cohort.

Results: In the exploratory cohort, 31 candidate biomarkers, including *KRAS/NRAS/BRAF* mutations, were identified. Targeted resequencing of 150 patients in the inference cohort revealed 40 patients with *RAS* (26.7%), 9 patients with $BRAF^{V600E}$ (6.0%), and 7 patients with $BRAF^{non-V600E}$ mutations (4.7%), respectively. The response rates in *RAS*, $BRAF^{V600E}$, and $BRAF^{non-V600E}$ were lower than those in *RAS/BRAF* wild-type (2.5%, 0%, and 0% vs 31.9%). The median PFS in $BRAF^{non-V600E}$ mutations was 2.4 months, similar to that in *RAS* or $BRAF^{V600E}$ mutations (2.1 and 1.6 months) but significantly worse than that in wild-type *RAS/BRAF* (5.9 months).

Conclusions: Although $BRAF^{non-V600E}$ mutations identified were a rare and unestablished molecular subtype, certain $BRAF^{non-V600E}$ mutations might contribute to a lesser benefit of anti-EGFR monoclonal antibody treatment.

*Correspondence: Dr T Yoshino; E-mail: tyoshino@east.ncc.go.jp

Received 4 April 2017; revised 5 August 2017; accepted 10 August 2017;
published online 3 October 2017

KRAS exon 2 mutations were the first validated predictive biomarker for primary resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab and panitumumab) in patients with metastatic colorectal cancer (mCRC) (Amado *et al*, 2008; Van Cutsem *et al*, 2009). Recently, minor *RAS* (*KRAS* exons 3 and 4 or *NRAS* exons 2, 3, and 4) mutations observed in ~15–20% of mCRC with wild-type *KRAS* exon 2 cases have been validated as negative predictive biomarkers for anti-EGFR antibody treatment (Douillard *et al*, 2013). Therefore, expanded *RAS* (*KRAS* and *NRAS*) testing before administration of anti-EGFR antibody treatment has become essential to maximise the therapeutic benefit in patients with mCRC (Taniguchi *et al*, 2015; Van Cutsem *et al*, 2015; Yoshino *et al*, 2015). However, the response rate (RR) to anti-EGFR monotherapy remains low, at ~20% in later line, in patients with mCRC having wild-type *RAS*, indicating additional biomarkers beyond expanded *RAS* are needed (Peeters *et al*, 2013).

BRAF is a serine-threonine kinase, located downstream of EGFR in the Ras/Raf/mitogen-activated protein kinase (MAPK) pathway (Mercer and Pritchard, 2003; Roskoski, 2010). The hotspot of *BRAF* mutations in CRC is substitution from valine to glutamic acid at codon 600 (V600E), located in exon 15, leading to 130- to 700-fold increased *BRAF* kinase activity compared with that of wild-type *BRAF*; these mutations are reported in ~5–12% of cases (Davies *et al*, 2002; Andreadi *et al*, 2012). In addition, *BRAF*^{V600E} mutations are more frequently observed in tumours in the right-sided colon than in tumours in the left-sided colon and rectum, and are prognostic biomarkers in CRC and could be potential predictive biomarker for anti-EGFR antibody treatment in pretreated mCRC (Kawazoe *et al*, 2015).

Recent clinical studies have shown that the primary location of the tumour may be associated with the therapeutic effects of anti-EGFR antibody treatment. Tumours in the right-sided colon showed worse outcomes than those in the left-sided colon and rectum in patients with mCRC with wild-type *RAS*, suggesting that genetic alterations other than *BRAF* V600E could be responsible for the poor prognosis of right-sided tumours (von Einem *et al*, 2014; Brulé *et al*, 2015).

In contrast, few reports have described mCRC with *BRAF* mutations other than *BRAF*^{V600E} (*BRAF*^{non-V600E} mutations), for which the incidence ranges from 1.6% to 5.1% (Shen *et al*, 2013; Ciardiello *et al*, 2014; Cremolini *et al*, 2015). *BRAF*^{non-V600E} mutations can be classified on the basis of kinase activity as either high activity, intermediate activity or impaired activity (130- to 700-fold; high activity mutants, 1.3- to 64-fold; intermediate activity mutants and 30–80%, respectively) (Wan *et al*, 2004). Furthermore, *BRAF* mutation with impaired kinase activity also enhances MAPK kinase (MEK) phosphorylation by heterodimerising with wild-type CRAF (Haling *et al*, 2014). However, little is known regarding the clinicopathological features and anti-EGFR antibody sensitivity of *BRAF*^{non-V600E}-mutated mCRC.

Here we reported the clinicopathological features of *BRAF*^{non-V600E}-mutated mCRC and the clinical significance of these mutations with regard to the therapeutic effects of anti-EGFR antibody treatment in pretreated mCRC.

MATERIALS AND METHODS

Study design. The Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics (BREAC) study was a multicentre, translational research study aiming to investigate novel predictive biomarkers of anti-EGFR antibody treatment in patients with mCRC harbouring wild-type or unknown *KRAS* exon 2 (details in Supplementary Protocol). We had the following study design; patients were divided into two

independent cohorts named ‘exploratory’ and ‘inference’ cohorts according to the duration of anti-EGFR antibody treatment. The exploratory cohort included subjects who were considered as ‘super-responders’ or ‘super-nonresponders’ among the entire mCRC cohort (403 patients) who received cetuximab including treatment as salvage line between September 2008 and May 2010 at seven major institutions in Japan. We put a strong assumption that associations between relatively minor gene mutations and patient prognosis become more remarkable in the ‘super-responders’ plus ‘nonresponders’ cohort than associations observed in the entire cohort, leading to a power increase in statistical tests (Supplementary Figure S1). The possible mutations founded in the exploratory cohort were then evaluated by targeted resequencing of the patients in the inference cohort who were treated by anti-EGFR antibody during the different period from the exploratory cohort.

Study conduct. In the inference cohort, patients with mCRC were consecutively enrolled between June 2010 and November 2011 from seven institutions to validate the associations of candidate biomarkers identified in the exploratory cohort with the efficacy of anti-EGFR antibody treatment in pretreated mCRC harbouring wild-type or unknown *KRAS* exon 2. The details of selection criteria for the inference cohort are described in the Supplementary Appendix.

This study was approved by the Institutional Review Board of each participating centre. Written informed consent was obtained from patients who were alive when initiating this study. For deceased patients and their relatives at that time, we disclosed the study design on the website of each centre and allowed the relatives to approve or deny inclusion in the study. This study was conducted in accordance with the Ethical Guidelines for the human genome and genetic analysis research of the Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare and Ministry of Economy, Trade and Industry.

Collection of clinical and pathological data. An electronic data capture system (Viedoc; PCG Solutions, Uppsala, Sweden) was used for registration of patients and collection of clinical and pathological data by the Office of Translational Research, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chiba, Japan.

Patient characteristics including age, sex, site of primary lesion, histology, site of metastases, prior treatments, clinical outcome of anti-EGFR antibody treatment, subsequent treatment, and severe adverse events related to anti-EGFR antibody treatment, were collected. Sites of primary lesions were divided into right-sided colon, left-sided colon, and rectum. Right-sided tumours were defined as those arising anywhere from the caecum to the transverse colon, and left-sided tumours were defined as those arising anywhere from the splenic flexure to the rectosigmoid junction.

Primary investigators were blinded to cancer genome alterations analysed in the study; investigators evaluated the antitumour effect according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer *et al*, 2009) and confirmed the safety of the treatment based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (National Cancer Institute, 2009).

Targeted capture resequencing. Archived FFPE tissue specimens collected before administration of anti-EGFR antibody were used for target resequencing. Candidate biomarkers identified from the exploratory cohort were validated by target resequencing, which covered the full length of all the candidate genes, including *KRAS*, *NRAS*, and *BRAF*. The details of preparation of clinical samples, DNA extraction, identification of single nucleotide variants (SNVs)

and insertion-deletion mutations (INDELs) and target resequencing are described in the Supplementary Appendix.

BRAF activity assay. To clarify the activity of newly identified *BRAF* mutations, we assessed the phosphorylation status of downstream molecules of EGFR by western blotting using HEK293 cells transfected with the *BRAF* mutant vector (Supplementary Appendix).

Statistical analysis. The efficacy endpoints were progression-free survival (PFS), defined as the duration from the initiation of anti-EGFR antibody treatment to disease progression or death from any cause; overall survival (OS), defined as the duration from the initiation of anti-EGFR antibody treatment to death from any cause; RR, defined as the proportion of patients who had a complete or partial response with anti-EGFR antibody treatment; and disease control rate (DCR), defined as the proportion of patients who had a complete or partial response or stable disease. For PFS and OS, survival curves according to each mutational status were estimated by the Kaplan–Meier method and were compared using log-rank test.

Univariate and multivariate Cox regression analyses were performed to evaluate the prognostic impact of any *RAS*/*BRAF*^{V600E}/*BRAF*^{non-V600E} mutant (herein referred to as *RAS*/*BRAF* mutant) *vs* wild-type. Covariates in the regression analyses included *RAS*/*BRAF* (mutant *vs* wild-type), age, gender, ECOG PS, histology, primary site, primary tumour resection, adjuvant chemotherapy, metastasis (synchronous *vs* metachronous), combined use of irinotecan, and prior oxaliplatin treatment. Considering the limited number of death events, backward elimination procedure, setting the removal criteria as a *P*-value of <0.20, was performed; four covariates (gender, ECOG PS, primary site, and combined use of irinotecan) were forcibly retained as potential confounding factors.

All statistical analyses were performed using SAS Release 9.3 (SAS Institute, Inc., Cary, NC, USA). All *P* values were obtained from two-sided statistical tests with a significance level of 0.05.

RESULTS

Summary of the exploratory cohort. In the exploratory cohort, 92 patients with mCRC, comprising 57 super-responders and 35 nonresponders to anti-EGFR antibody treatment (90 *KRAS* exon 2 wild type and 2 unknown), were selected (Supplementary Figure S2). FFPE clinical samples of both cancerous and noncancerous areas were subjected to whole exon sequencing. Briefly, the exomes were captured using the SureSelect Human All Exon V4 + UTRs Kit (Agilent Technologies) and sequenced using a HiSeq 2000 system (Illumina) to generate 100 bpbpaired-end data. The average base coverage of the targeted regions in the tumour and normal samples was 162.5-fold (range: 10.2–389.7) and 166.2-fold (range: 2.7–377.4), respectively. We identified 182.7 ± 97.1 (range: 37.0–509.0) (5.7 ± 3.0 per Mb, range: 1.2–15.9) somatic SNVs and 8.1 ± 4.2 (range: 1.0–23.0) (0.3 ± 0.1 per Mb, range: 0.0–0.7) somatic INDELs in the tumour tissues. Thirty-one candidate

biomarker genes, including *KRAS*/*NRAS*/*BRAF*, in which mutations significantly deviated from either super-responders or nonresponders, were selected for further analysis with the inference cohort. Detailed data of the exploratory cohort is described elsewhere. Here we focused on the association of expanded *RAS* and *BRAF* mutation with efficacy endpoints in the inference cohort.

Genomic alternations and patient characteristics according to *RAS*/*BRAF* status in the inference cohort. A total of 184 patients were selected in the inference cohort. Target resequencing of the candidate biomarker genes, including *KRAS*/*NRAS* and *BRAF*, was successful in 156 patients, while 28 clinical samples were not analysed due to insufficient FFPE samples (*n* = 6) and sequencing failure (*n* = 22). The average base coverage of the targeted regions in the tumour and normal samples was 671.9-fold (range: 66.8–1735.0) and 731.6-fold (range: 70.4–1699.5), respectively. We identified 1.4 ± 1.3 (range: 0.0–8.0) variants in the 31 candidate genes from tumour tissues. Additionally, six patients were excluded due to ineligibility (*n* = 5) and acquisition of the specimen after anti-EGFR antibody treatment (*n* = 1). Accordingly, 150 patients were included in the biomarker analysis population (Supplementary Figure S3). Baseline patient characteristics and clinical outcomes were similar between the whole population (*N* = 184) and biomarker analysis population (*N* = 150; data not shown).

KRAS, *NRAS*, and *BRAF* mutations were detected in 29 (19.3%), 11 (7.3%), and 16 (10.7%) patients, respectively. *RAS* and *BRAF* mutations were identified in a mutually exclusive manner. Nine of 16 *BRAF* mutations (6.0%) were *BRAF*^{V600E} mutations, and seven were *BRAF*^{non-V600E} mutations (4.7%) located in the kinase domain as one G469A (high activated subtype in exon 11) with co-mutation of *MAP2K1*, one L485F (intermediate subtype in exon 12), one Q524L, one L525R (intermediate subtypes in exon 13), two D594G (impaired subtype in exon 15) and one V600R (high subtype in exon 15) with co-mutations of *MSP2* and *PPFIA2* (Table 1). Q524L and L525R were newly identified mutations that were not registered in either the Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov>) or the Catalogue of Somatic Mutation in Cancer (COSMIC; <http://cancer.sanger.ac.uk/cosmic>) databases.

Baseline patient characteristics, based on the *RAS* and *BRAF* mutational status, are shown in Table 2. Both *BRAF*^{V600E} and *BRAF*^{non-V600E} mutant tumours were more commonly associated with the right-sided colon (44.4% and 57.1%, respectively) than the *RAS*/*BRAF* wild-type and *RAS* mutant tumours (13.8% and 27.5%, respectively). *BRAF*^{non-V600E} mutant tumours tended to have more lymph node metastases (71.4%) than with other mutational subtypes, *RAS* and *BRAF*^{V600E} mutations (27.5% and 11.1%, respectively).

R Rs to anti-EGFR antibody treatment according to *RAS*/*BRAF* mutation status in the inference cohort. The RR was 20.7% in all patients. The RRs in patients with *RAS*, *BRAF*^{V600E}, and *BRAF*^{non-V600E} mutations were lower in comparison with patients harbouring wild-type *RAS*/*BRAF* (2.5%, 0%, and 0% *vs* 31.9%, respectively).

Table 1. Genomic alternations detected by targeted resequencing of the BRAF ^{non-V600E} mutation							
ID	GQ0XS	GLCH7	SC12PCQ3IA02	G9OJR	GQ4U5	GUZG7	GS3A5
hg19 position	140481402	140477853	140476835	140476832	140453154	140453154	140453136-140453137
Amino acid variation	G469A	L485F	Q524L	L525R	D594G	D594G	V600R
Kinase activity	Activated	Activated	NR	NR	Impaired	Impaired	Activated
Co-mutations	MAP2K1	—	—	—	—	—	MAP2, PPFIA2
Abbreviation: NR = not reported.							

Table 2. Baseline patient characteristics according to RAS/BRAF mutational status

	RAS/BRAF wild		RAS mut		BRAF ^{V600E} mut		BRAF ^{non-V600E} mut	
	(n = 94)		(n = 40)		(n = 9)		(n = 7)	
	No	%	No	%	No	%	No	%
Age, years								
Median	64		63		64		63	
Range	28–85		35–79		33–73		48–74	
Gender								
Male	64	68.1	18	45	4	44.4	1	14.3
Female	30	31.9	22	55	5	55.6	6	85.7
ECOG PS								
0	53	56.4	22	55	3	33.3	3	42.9
1	38	40.4	17	42.5	6	66.7	4	57.1
2	3	3.2	1	2.5	0	0	0	0
Histology ^a								
Well	17	18.1	11	27.5	1	11.1	1	14.3
Moderate	62	66	23	57.5	6	66.7	5	71.4
Poor	11	11.7	5	12.5	1	11.1	1	14.3
Others	4	4.3	1	2.5	1	11.1	0	0
Primary tumour site ^b								
Right-sided colon	13	13.8	11	27.5	4	44.4	4	57.1
Left-sided colon or rectum	81	86.2	29	72.5	5	55.6	3	42.9
Resection of primary tumour								
	77	81.9	35	87.5	8	88.9	7	100
Time to metastases								
Synchronous	50	53.2	20	50	4	44.4	1	14.3
Metachronous	44	46.8	20	50	5	55.6	6	85.7
Number of metastases								
1	33	35.1	10	25	5	55.6	0	0
> 1	61	64.9	30	75	4	44.4	7	100
Metastatic site								
Liver	61	64.9	25	62.5	4	44.4	4	57.1
Lung	49	52.1	27	67.5	3	33.3	6	85.7
Peritoneum	20	21.3	9	22.5	3	33.3	2	28.6
Lymph node	37	39.4	11	27.5	1	11.1	5	71.4
Reason of discontinuation for each cytotoxic agent as prior treatment								
Fluoropyrimidine								
Failure	94	100	40	100	9	100	7	100
Intolerance	0	0	0	0	0	0	0	0
Oxaliplatin								
Failure	83	88.3	38	95	9	100	5	71.4
Intolerance	11	11.7	2	5	0	0	2	28.6
Irinotecan								
Failure	94	100	40	100	9	100	7	100
Intolerance	0	0	0	0	0	0	0	0
Prior Bevacizumab								
	74	78.7	33	82.5	8	88.9	7	100
Anti-EGFR antibody treatment								
Cetuximab	66	70.2	29	72.5	6	66.7	5	71.4
Panitumumab	28	29.8	11	27.5	3	33.3	2	28.6
Combine use of Irinotecan								
Yes	69	73.4	35	87.5	8	88.9	4	57.1
No	25	26.6	5	12.5	1	11.1	3	42.9

Abbreviations: ECOG=Eastern Cooperative Oncology Group; FP=fluoropyrimidine; mut=mutant; poor=poorly differentiated; well=well differentiated; moderate, moderately differentiated; wild=wild-type. Wild-type RAS/BRAF was defined as all wild-type sequence with RAS, BRAF^{V600E}, and BRAF^{non-V600E}.

^aDefined according to Japanese Classification (ref: JSCCR, Japanese Classification of Colorectal Carcinoma, 2nd English Ed).

^bRight-sided tumours were defined as those arising anywhere from the caecum to the transverse colon, and left-sided tumours were defined as those arising anywhere from the splenic flexure to the rectosigmoid junction.

Abbreviations: ECOG = Eastern Cooperative Oncology Group; FP = fluoropyrimidine; mut = mutant; poor = poorly differentiated; well = well differentiated; moderate, moderately differentiated; wild = wild-type. Wild-type RAS/BRAF was defined as all wild-type sequence with RAS, BRA^{V600E}, and BRA^{non-V600E}.

^aDefined according to Japanese Classification (ref: JSCCR, Japanese Classification of Colorectal Carcinoma, 2nd English Ed).

^bRight-sided tumours were defined as those arising anywhere from the caecum to the transverse colon, and left-sided tumours were defined as those arising anywhere from the splenic flexure to the rectosigmoid junction.

In addition, the proportion of SD more than 6 months in patients with BRA^{non-V600E} mutant was 14.3%, which was similar to that in patients with RAS or BRA^{V600E} mutations rather than wild-type RAS/BRAF (Table 3).

Survival and safety analysis according to RAS and BRAF status in the inference cohort. The median follow-up time was 12.1 months as of the cutoff date of December 24, 2014. The median PFS and OS of all patients were 4.0 months (95% confidence

Table 3. Efficacy of anti-EGFR antibody treatment according to the RAS/BRAF mutational status								
	RAS/BRAF wild		RAS mut		BRAF ^{V600E} mut		BRAF ^{non- V600E} mut	
	(n = 94)		(n = 40)		(n = 9)		(n = 7)	
PFS, months								
Median	5.9		2.1		1.6		2.4	
95% CI	4.9–7.7		1.9–2.6		1.1–3.4		2.1–4.0	
OS, months								
Median	14.5		6.3		4.6		8.1	
95% CI	12.6–16.2		4.6–8.4		1.3–21.2		5.3–16.9	
RR, %								
	31.9		2.5		0		0	
95% CI	22.7–42.3		0.1–13.2		0.0–33.6		0.0–41.0	
Response, No, %								
CR	0	0	0	0	0	0	0	0
PR	30	31.9	1	2.5	0	0	0	0
Long SD > 6 months	45	47.9	3	7.5	1	11.1	1	14.3
Abbreviations: CR = complete response; DCR = disease control rate; mut = mutant; NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease; wild = wild-type. Wild-type RAS/BRAF was defined as all wild-type sequences with RAS, BRAF ^{V600E} , and BRAF ^{non-V600E} .								

interval (CI), 3.4–4.8 months) and 12.4 months (95% CI, 9.8–14.0), respectively.

The median PFS of patients with *BRAF*^{non-V600E} mutations was 2.4 months (95% CI, 2.1–4.0), similar to that in patients with *RAS* or *BRAF*^{V600E} mutations (2.1 months, 95% CI, 1.9–2.6 and 1.6 months, 95% CI, 1.1–3.4, respectively) but significantly worse than that in patients with wild-type *RAS/BRAF* (5.9 months, 95% CI, 4.9–7.7, *P* < 0.0001; Table 3, Figure 1).

The median OS of patients with *BRAF*^{non-V600E} mutations was 8.1 months (95% CI, 5.3–16.9), similar to that in patients with *RAS* or *BRAF*^{V600E} mutations (6.3 months, 95% CI, 4.6–8.4 and 4.6 months, 95% CI, 1.3–21.2, respectively) but worse than that in patients with wild-type *RAS/BRAF* (14.5 months, 95% CI, 12.6–16.2; Table 3, Figure 1).

Univariate and multivariate analyses for PFS and OS. Univariate and multivariate analyses for PFS and OS are shown in Table 4. Mutation subtype with *RAS/BRAF* was a strong negative prognostic factor for both PFS (HR, 3.49; 95% CI, 2.43–5.00) and OS (HR, 2.14; 95% CI, 1.51–3.04) in univariate analyses. Similarly, the *RAS/BRAF* subtype was also a strong negative prognostic factor for both PFS (HR, 5.43; 95% CI, 3.45–8.55) and OS (HR, 3.37; 95% CI, 2.20–5.16) in multivariate analyses.

BRAF activity assays for the newly identified mutations Q524L and L525R. To evaluate the kinase activity of newly identified *BRAF* mutants, mutant- and wild-type *BRAF*-expressing vectors were transiently transfected into EGFR-expressing HEK293 cells. The transfection efficiency was more than 70%, as assessed by EGFR-expressing control plasmid vector transfection (data not shown). Western blot analysis showed that extracellular signal-regulated kinase (ERK) phosphorylation in cells with *BRAF*^{V600E} overexpression was significantly increased compared with that in cells with wild-type *BRAF* overexpression (Figure 2). *BRAF*^{L525R} induced increased ERK phosphorylation to a level similar to that induced by *BRAF*^{V600E}. However, *BRAF*^{Q524L} activity was similar to that of wild-type *BRAF*.

In the control vector-transfected cells, cetuximab reduced ERK phosphorylation in a concentration-dependent manner. Additionally, cetuximab reduced ERK phosphorylation level, which was enhanced by wild-type *BRAF* or *BRAF*^{Q524L} expression. On the other hand, ERK phosphorylation enhanced by *BRAF*^{V600E} and

Figure 1. Merged survival curves for anti-EGFR antibody treatment. Kaplan–Meier curves for (A) progression-free survival (PFS) and (B) overall survival (OS) from the initiation of anti-EGFR antibody treatment in patients with pretreated mCRC according to mutational status. Wild-type *RAS/BRAF* was defined as all wild-type sequences with *RAS*, *BRAF*^{V600E} and *BRAF*^{non-V600E}. A total of 150 patients in the inference cohort were classified according to *RAS/BRAF* WT (*n* = 94); *RAS* MT (*n* = 40); *BRAF*^{V600E} MT (*n* = 9); and *BRAF*^{non-V600E} MT (*n* = 7). For comparison, Kaplan–Meier curves of *RAS* WT (*n* = 110; yellow solid) and *RAS/BRAF*^{V600E} WT (*n* = 101; blue solid) were added. MT, mutant; WT, wild-type.

BRAF^{L525R} was not affected by cetuximab, suggesting that cells with *BRAF*^{V600E} or *BRAF*^{L525R} mutants were resistant to cetuximab-induced inhibition of EGFR.

DISCUSSION

To the best of our knowledge, this is the first report for the clinical significance of *BRAF*^{non-V600E} mutations focusing on the therapeutic effects of anti-EGFR monoclonal antibodies in patients with pretreated mCRC.

Few studies have reported the clinicopathological features of *BRAF*^{non-V600E} mutations because *BRAF*^{V600E}-mutant tumours are most frequently observed in CRC (Shen *et al*, 2013; Ciardiello *et al*, 2014). According to studies in Western countries, the incidence of *BRAF*^{non-V600E} in mCRC was reported to range from 1.6% to 2.7% (Ciardiello *et al*, 2014; Cremolini *et al*, 2015). In contrast, the incidence of *BRAF*^{non-V600E} in 676 Chinese patients with mCRC was reported to be 5.1%, consistent with that in our cohort (4.7%) (Shen *et al*, 2013). On the other hand, the racial differences in terms of the incidence of *BRAF*^{V600E} mutations were reported from

Table 4. Univariate and multivariate analysis with RAS/BRAF as a covariate for OS and PFS								
	PFS				OS			
	Univariate		Multivariate		Univariate		Multivariate	
	HR	p	HR	p	HR	p	HR	p
RAS/BRAF								
Mutant/wild-type	3.49	<0.0001	5.43	<0.0001	2.14	<0.0001	3.37	<0.0001
Age								
	0.98	0.0078	0.98	0.0547	0.98	0.0493	excluded	
Gender								
Female/male	1.27	0.1585	0.78	0.1852	1.48	0.0268	0.84	0.405
ECOG PS								
1,2/ 0	1.12	0.4919	1.17	0.3854	1.16	0.3979	1.06	0.7609
Histology								
Well/others	1.93	0.1471	3.12	0.021	1.99	0.159	2.58	0.0597
Moderate/others	1.79	0.169	4	0.0028	1.86	0.179	3.28	0.0139
Poor/others	1.6	0.3193	2.6	0.0691	2.32	0.1	4	0.009
Primary site								
Right-sided/others	1.3	0.1974	1.52	0.0641	1.38	0.1335	1.73	0.0213
Resection ^a								
Yes/no	0.91	0.6776	excluded		0.74	0.2038	excluded	
Adjuvant chemotherapy								
Yes/no	0.87	0.4153	0.7	0.048	0.5	0.0036	0.64	0.1202
Metastasis								
Synchronous/metachronous	0.87	0.4153	0.7	0.048	0.62	0.0058	0.43	0.0001
Combined with irinotecan								
Yes/no	0.69	0.0649	0.52	0.0042	0.67	0.0524	0.42	0.0004
Prior Ox ^b								
Intolerance/failure	0.55	0.0322	0.63	0.1322	0.53	0.0383	0.38	0.0035
Abbreviations: ECOG = Eastern Cooperative Oncology Group; moderate = moderately differentiated; poor = poorly differentiated; PS = performance status; well = well differentiated.								
^a Primary tumour resection.								
^b Prior oxaliplatin treatment; wild-type RAS/BRAF was defined as all wild-type sequences with RAS, BRAF ^{V600E} , and BRAF ^{non-V600E} .								

the analysis of large-scale adjuvant trial in US, suggesting the incidence appeared to be lower in Asians than in blacks or whites (Yoon *et al*, 2015). Instead, the incidence of BRAF^{non-V600E} mutations might be higher in Asian than that in Caucasian patients.

Two meta-analyses suggested that primary tumours in the right-sided colon showed worse prognoses than those in the left-sided colon and rectum in patients treated with anti-EGFR antibodies (Arnold *et al*, 2017; Holch *et al*, 2017). In addition, integrated analysis of two randomised panitumumab studies showed that they had consistent results, even when the BRAF^{V600E} mutations were excluded (Boeckx *et al*, 2017). In our series, a similar tendency was observed clinical outcomes; specifically, patients with wild-type RAS mCRC with primary tumours in the right-sided colon had poorer prognoses compared with those having primary tumours in the left-sided colon and rectum, although the difference was not significant. However, if limited to wild-type RAS/BRAF tumours, there were no clear differences in OS among sites of primary lesions (Supplementary Figure 4). Thus, the unresponsiveness of primary tumours in the right-sided colon to anti-EGFR antibodies in later line might be partially explained by underlying BRAF^{non-V600E}-mutated tumours.

Subtypes of BRAF mutations in the kinase domain can be classified into high, intermediate, and impaired activity subtypes based on their kinase activity (Wan *et al*, 2004). The BRAF^{V600E} mutation belongs to the high activity subtype, whereas the BRAF^{G469A}, BRAF^{L485F}, and BRAF^{V600K} mutations observed in this study belong to the intermediate subtype and the BRAF^{D594G} mutation belongs to the impaired subtype. Moreover, the

Figure 2. BRAF activity assay. Phosphorylation status of ERK was assessed by western blotting. HEK293 cells were transiently transfected with wild-type, V600E, Q524L, or L525R BRAF and were then treated with 0.5 or 5 μg/ml cetuximab.

BRAF^{L525R} mutant observed in this study had enhanced kinase activity, and the enhanced downstream signal of BRAF^{L525R} may contribute to primary resistance to cetuximab, consistent with the lack of response to anti-EGFR antibody treatment in our series. In contrast, the newly identified BRAF^{Q524L} mutant identified in this study had intermediate kinase activity and did not induce resistance to cetuximab in an *in vitro* cell model. However, such *in vitro* experiments in non-CRC epithelial cell lines may not fully predict the clinical outcome.

One possible explanation for the similar behaviours of BRAF^{non-V600E} and BRAF^{V600E}-mutated tumours in terms of unresponsiveness to anti-EGFR antibody treatment may be the incomplete blockade of the MEK pathway by modestly upregulated kinase activity of BRAF and/or by additional signalling through

wild-type CRAF (Wan *et al*, 2004). Therefore, it is necessary to establish patient-derived xenograft models harbouring BRAF^{non-V600E} mutations to clarify the mechanisms of primary resistance to anti-EGFR antibody treatment in BRAF^{non-V600E}-mutated mCRC.

Regarding BRAF^{D594G}, classified as an impaired subtype in the study, Cremolini *et al* reported 10 cases with BRAF mutations in codons 594 or 596, the number of which was similarly small showing a favourable prognosis from first line (Cremolini *et al*, 2015). More recently, it was reported that OS was significantly longer for 101 patients with BRAF^{non-V600E} mutations than for the control group of 99 patients with BRAF^{V600E} mutations (60.7 vs 11.4 months) (Jones *et al*, 2017); however, our analysis focused on pretreated population. In addition, according to the European Consortium, De Roock *et al* reported that two patients harbouring BRAF^{D594G}-mutated mCRC achieved a partial response to cetuximab monotherapy (De Roock *et al*, 2010). In contrast, the two patients with BRAF^{D594G}-mutated tumours in our study did not achieve objective response to anti-EGFR antibody treatment. Considering small patient's number of each reports as well as heterogeneous population, it is difficult to conclude predictive impact of BRAF^{non-V600E} mutation. The overall data in this study supported that BRAF^{non-V600E} mutations were prognostic, as a similar magnitude to the presence of BRAF^{V600E} and RAS mutations in later line, and the outcome appeared similar to patients with RAS mutations as well, who do not benefit from anti-EGFR therapy. The present study has some limitations. It was a retrospective study with a small number of subgroups of BRAF^{non-V600E} mutations, using archived FFPE samples. In addition, it is difficult to conduct further analyses by subdividing the group into 'non-V600E kinase activity' and 'non-V600E non-kinase activity' subgroups, due to the small number of BRAF^{non-V600E} mutations. The emergence of secondary RAS and BRAF gene mutations in ctDNA was recently reported after treatment with anti-EGFR antibody (Bettegowda *et al*, 2014). However, in the case of patients receiving systemic chemotherapy without anti-EGFR antibody, secondary gene alterations are rare (Kawamoto *et al*, 2012); therefore, we believed that adding the archived FFPE samples before anti-EGFR antibody administration would be reasonable. Further investigation in large-scale data set from such as randomised control trials is necessary to clarify the significance of anti-EGFR antibody treatment for each BRAF^{non-V600E} mutational variants as the role of the predictive value.

In conclusion, although identified BRAF^{non-V600E} mutations were rare and unestablished molecular subtype in mCRC, overall clinical outcomes of BRAF^{non-V600E} mutations in the kinase domain, similar to those of RAS- and BRAF^{V600E}-mutant tumours, appeared to be significantly worse than those in wild-type RAS/BRAF tumours. Certain BRAF^{non-V600E} mutations might contribute to a lesser benefit of anti-EGFR monoclonal antibody treatment. This novel knowledge provides an intriguing background to investigate new target approaches in patients with BRAF^{non-V600E} mutations and represents substantial progression toward more precision medicine.

ACKNOWLEDGEMENTS

We would like to express special thanks to all participating patients and their families; all investigators, including the participating radiologists Takeshi Aramaki and Toshihiro Iguchi; and Izumi Miki, Akiko Nakayama, and Yoriko Kato at the Office of Translational Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan. The BREAC study was supported by the Adaptable and Seamless Technology Transfer Program (ASTEP) through target-driven R&D, Practical Application Development by SME Start-up, Japan

Science and Technology Agency (JST), National Cancer Center Research and Development Fund (23-A-2), G & G Science Co., Ltd., and Medical & Biological Laboratories Co., Ltd.

Presentations: American Society of Clinical Oncology Annual Meeting, Chicago, May 2015 and Gastrointestinal Cancers Symposium, San Francisco, January 2015.

¹⁹These authors contributed equally to this work.

²⁰Present address: Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

²¹Present address: Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Conception and design: TY, KT, SF, YS, KA, HE, MS, NN, MM, YK, YA, and AO. Provision of study materials or patients: ES, KY, TY, KM, TN, KY, SY KS, and HB. Collection and assembly of data: TY and SN. Genome sequencing: SM, CN, and KT. Cell-based experiments: KM and CN. Data analysis and interpretation: All authors. Manuscript writing: TY, KT, and ES. Final approval of manuscript: All authors.

REFERENCES

- Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* **26**: 1626–1634.
- Andreoli C, Noble C, Patel B, Jin H, Aguilar Hernandez MM, Balmanno K, Cook SJ, Pritchard C (2012) Regulation of MEK/ERK pathway output by subcellular localization of B-Raf. *Biochem Soc Trans* **40**: 67–72.
- Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. *Ann Oncol* **28**: 1713–1729.
- Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Lubner B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih IM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr (2014) Detection of circulating tumour DNA in early- and late-stage human malignancies. *Sci Transl Med* **6**(224): 224ra24.
- Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M (2017) Primary tumour sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomised first-line panitumumab studies. *Ann Oncol* **28**(8): 1862–1868.
- Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA (2015) Location of colon cancer (right-sided vs left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. *Eur J Cancer* **51**: 1405–1414.
- Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Piscanti S, Giuliani F, Barone C, Carteni G, Rachiglio AM, Montesarchio V, Tonini G,

- Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G (2014) Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. *Ann Oncol* **25**: 1756–1761.
- Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F (2015) BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. *Ann Oncol* **26**: 2092–2097.
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake G, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. *Nature* **417**: 949–954.
- De Rooij W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeris KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* **11**: 753–762.
- Douillard J-Y, Oliner KS, Siena S, Abernethy J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassam J, Rivera F, Kocakova I, Ruff P, Blasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* **369**: 1023–1034.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* **45**(2): 228–247.
- Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S (2014) Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling cancer. *Cell* **26**: 402–413.
- Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V (2017) The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *Eur J Cancer* **70**: 87–98.
- Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A (2017) Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. *J Clin Oncol* **35**(23): 2624–2630.
- Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A (2012) KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. *Br J Cancer* **107**(2): 340–344.
- Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T (2015) A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. *BMC Cancer* **15**: 258.
- Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. *Biochim Biophys Acta* **1653**: 25–40.
- National Cancer Institute (2009) NIH Publication No. 09-5410. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
- Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, André T, Wiezorek J, Reese D, Patterson SD (2013) Massively parallel tumour multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. *Clin Cancer Res* **19**: 1902–1912.
- Roskoski R (2010) RAF protein-serine/threonine kinases: Structure and regulation. *Biochem Biophys Res Commun* **399**: 313–317.
- Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y (2013) Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. *PLoS ONE* **8**: e81628.
- Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K. Japanese Society of Medical Oncology (2015) Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. *Cancer Sci* **106**: 324–327.
- Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* **360**: 1408–1417.
- Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. *J Clin Oncol* **33**: 692–700.
- von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, Kirchner T, Haas M, Holch J, Michl M, Aubele P, Boeck S, Schulz C, Giessen C, Stintzing S, Modest DP (2014) Left-sided primary tumours are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. *J Cancer Res Clin Oncol* **140**: 1607–1614.
- Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Cancer Genome Project (2004) Mechanism of activation of the Raf-MEK signaling pathway by oncogenic mutations of B-Raf. *Cell* **116**: 856–867.
- Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA. Alliance for Clinical Trials in Oncology (2015) Racial differences in BRAF/KRAS mutation rates and survival in stage III colon cancer patients. *J Natl Cancer Inst* **107**(10): djv186.
- Yoshino T, Muro K, Yamaguchi K, Nishina T, Denda T, Kudo T, Okamoto W, Taniguchi H, Akagi K, Kajiura T, Hironaka S, Satoh T (2015) Clinical validation of a multiplex kit for RAS mutations in colorectal cancer: results of the RASKET (RAS KEy Testing) prospective, multicenter study. *EBioMedicine* **2**: 317–323.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) named above 2017

¹Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-0063, Japan; ²Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan; ³Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan; ⁴Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan; ⁵Department of Gastroenterology, Saitama Cancer Center, Saitama 362-0806, Japan; ⁶Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan; ⁷Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo 060-8648, Japan; ⁸Division of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba 277-8577, Japan; ⁹G&G Science Co. Ltd., Fukushima 960-1242, Japan; ¹⁰Department of Computational Biology, Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277-8562, Japan; ¹¹Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama 362-0806, Japan; ¹²Department of Biostatistics, National Cancer Center, Kashiwa 277-8577, Japan; ¹³Biostatistics Division, Center for Research and Administration and Support, National Cancer Center, Kashiwa 277-8577, Japan; ¹⁴Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan; ¹⁵Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba 278-8510, Japan; ¹⁶Genome Medical Science Project, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba 272-8516, Japan; ¹⁷Third Department of Internal Medicine, Wakayama Medical University, Wakayama 641-8509, Japan and ¹⁸Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba 277-8577, Japan

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)